sdbn.org

Drug Development, News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Amylin, Optimer, and the Economy
Posted by sandiegobiotech February 3rd, 2012 .
No Comments

—San Diego’s Amylin Pharmaceuticals says Bydureon, its new once-a-week drug for treating Type 2 diabetes can hit the market as early as next month, after the FDA cleared Bydureon. The FDA rejected...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Vertex’s Big Day Felt Like Moon Landing, Seattle Researcher Says
Posted by sandiegobiotech February 1st, 2012 .
No Comments

Bonnie Ramsey said three years ago that a cystic fibrosis drug from Vertex Pharmaceuticals was a huge medical advance in the making, and would end up being an achievement on par with putting a man on...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Vertex Gets FDA Go-Ahead To Sell New Cystic Fibrosis Drug
Posted by sandiegobiotech January 31st, 2012 .
No Comments

[Updated: 1:25 pm] Vertex Pharmaceuticals is now officially more than just a one-hit wonder. The Cambridge, MA-based biotech company (NASDAQ: VRTX), best known for its hepatitis C drug, has won...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Optimer, Following Pfizer’s Playbook, Has Big Plans for Antibiotic
Posted by sandiegobiotech January 31st, 2012 .
No Comments

Pfizer was where Pedro Lichtinger learned about pharmaceutical marketing from people who did some amazing things. For starters, New York-based Pfizer (NYSE: PFE) turned an old-school antifungal...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Four Themes to Watch in Personalized Medicine
Posted by sandiegobiotech January 30th, 2012 .
No Comments

Good morning from Mountain View, CA, and from the close of the 2012 Personalized Medicine World Conference, which brought together thought leaders of business, government, healthcare-delivery,...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Never Back Smug: A Lesson for Life Sciences From Newt Gingrich
Posted by sandiegobiotech January 30th, 2012 .
No Comments

Newt Gingrich comes across on TV as someone who radiates smugness. It’s that sense that he’s not just confident in his own abilities, but extremely satisfied with his talents and his utter...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Amylin, Alkermes Win FDA Approval of Once-Weekly Diabetes Drug
Posted by sandiegobiotech January 27th, 2012 .
No Comments

[Updated: 3:47 pm] Amylin Pharmaceuticals and Alkermes have gone to the FDA twice before to seek approval of their new diabetes drug, and been turned back, but now the persistence has paid off. The...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

2012 Venture Outlook: Some Bright Spots and Some Gloom
Posted by sandiegobiotech January 27th, 2012 .
No Comments

It’s that outlook time of year, and Mark Heesen, president of the National Venture Capital Association (NVCA), was in San Diego earlier this week, talking about the 2012 outlook for venture capital....

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Why Biogen Idec Got Out of the Corporate VC Business
Posted by sandiegobiotech January 27th, 2012 .
No Comments

Steve Holtzman got his first taste of corporate venture capital back in 1987, when he raised money from SR One, back when it was part of an old company known as Smith, Kline & French. The concept...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Roche Makes $5.7B Hostile Takeover Bid for Illumina
Posted by sandiegobiotech January 25th, 2012 .
No Comments

San Diego-based Illumina, the market leading maker of DNA sequencing instruments, has just made it through a rough year, and now it may be entering its final chapters as an independent company....

[[Click headline to continue reading.]] More...